Literature DB >> 1276479

Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A.

J P Allain, D Frommel.   

Abstract

The natural history of factor VIII antibodies was studied in 20 severe, multitransfused hemophiliacs. Two patterns of humoral immune reactivity were observed. In one group of ten, who developed antibodies after an average of 22 cumulative exposure days to factor VIII, the antibody titers increased after each antigenic stimulation or persisted for years in the absence of transfusion. These patients were designated as high-responding hemophiliacs. In the second group of ten patients, the factor VIII neutralizing activity appeared after a longer exposure period (48 days). Antibody titers remained low, and there was no significant difference in individual titers before and 8--20 days following transfusion. Antibody affinity did not increase after renewed antigenic challenge. This pattern characterized low-responding hemophiliacs. The latter group of patients benefited from repeated placement therapy required by the clinical situation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1276479

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes.

Authors:  E T Zambidis; A Kurup; D W Scott
Journal:  Mol Med       Date:  1997-03       Impact factor: 6.354

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Hepatitis C treatment with triple therapy in a patient with hemophilia A.

Authors:  Gurshawn Singh; Reuben Sass; Rayan Alamiry; Nizar Zein; Naim Alkhouri
Journal:  World J Clin Cases       Date:  2013-06-16       Impact factor: 1.337

4.  The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.

Authors:  Ian W Smith; Anne E d'Aquino; Christopher W Coyle; Andrew Fedanov; Ernest T Parker; Gabriela Denning; Harold Trent Spencer; Pete Lollar; Christopher B Doering; Paul Clint Spiegel
Journal:  J Thromb Haemost       Date:  2019-09-08       Impact factor: 5.824

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.